Christian Angermayer, the founder of Neurobotics Health, recently completed the sale of his psychedelic drug development firm to Eli Lilly and Company for approximately $360 million. The deal marks a significant financial windfall for Angermayer, who founded Neurobotics Health in 2014 after having an experience with psilocybin mushrooms that he believed could lead to breakthroughs in mental health treatments.
Angermayer's journey began when he had a transformative psychedelic trip twelve years ago. This experience inspired him to develop pharmaceutical-grade versions of naturally occurring compounds found in plants and fungi, including psilocybin, MDMA, and ketamine. His company focused on creating FDA-approved medicines from these substances, aiming to address conditions such as depression, anxiety, PTSD, and addiction.
The sale to Eli Lilly is not the first time Angermayer has leveraged his psychedelic research for financial gain. In 2019, he sold a minority stake in Neurobotics Health to private equity firm Cerberus Capital Management for $35 million. This transaction was part of a broader strategy aimed at diversifying his portfolio and securing funding for further research.
The acquisition by Eli Lilly is expected to bolster the company's position in the rapidly growing field of psychedelic therapeutics, which has seen increased interest from both pharmaceutical companies and investors due to its potential benefits in treating various mental health conditions. The deal also reflects a shift towards more conventional approaches within the psychedelics industry, as major pharma firms seek to capitalize on what they see as promising therapeutic opportunities.
[1] [2]